20:27:04 EDT Fri 17 May 2024
Enter Symbol
or Name
USA
CA



Cutera Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

2023-10-06 17:00 ET - News Release


BRISBANE, Calif. -- (Business Wire)

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that on October 3, 2023 the Compensation Committee of Cutera’s Board of Directors approved the grant of inducement awards to Brent Hauser, who joined Cutera on October 2, 2023, as the President, International. The inducement awards consisted of restricted stock units (RSUs) settleable in 27,358 shares of common stock, and two grants of performance stock units (PSUs) settleable in 54,716 shares of common stock and 25,000 shares of common stock, respectively.

The RSUs were granted on October 3, 2023. A quantity of 25% shall vest on October 2, 2024, and 1/12 of the RSUs shall vest each quarter thereafter, subject to Mr. Hauser continuing as an employee.

The PSU grants were granted on October 3, 2023. Regarding the PSU grant of 54,716 shares of common stock, the performance-based vesting schedule and targets will be determined by Cutera’s Board of Directors or Compensation Committee. The PSU grant of 25,000 shares of common stock has a single performance criteria of the 30-calendar day trailing average of Cutera’s closing common stock price exceeding $20.00 within four years of the grant date.

Each inducement award is subject to the terms of the Cutera, Inc. 2023 Inducement Equity Incentive Plan and related forms of agreements and were granted as inducements material to these employees to enter into employment with Cutera in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com.

Contacts:

Greg Barker
VP, Corporate FP&A and Investor Relations
415-657-5500
IR@cutera.com

Source: Cutera, Inc.

© 2024 Canjex Publishing Ltd. All rights reserved.